I am familiar with this research, as well as how the US big pharma operates.
All that aside,
The core issue globally IS overuse.
And it IS true that we have made bacteria resistant to major pathways. Now we are exploiting new ones but the effectiveness and RoI is declining.
New drugs won’t save us. They won’t even hold the line forever. The best new drugs would be kept in reserve by doctors for the most serious resistant strains, which is why there is low commercial interest. The resistance drives this dynamic.
I am familiar with this research, as well as how the US big pharma operates.
All that aside,
The core issue globally IS overuse.
And it IS true that we have made bacteria resistant to major pathways. Now we are exploiting new ones but the effectiveness and RoI is declining.
New drugs won’t save us. They won’t even hold the line forever. The best new drugs would be kept in reserve by doctors for the most serious resistant strains, which is why there is low commercial interest. The resistance drives this dynamic.